Elucidating the role of alpha2beta1 integrin in the chemoresistance of acute lymphoblastic leukemia.

阐明α2β1整合素在急性淋巴细胞白血病化疗耐药中的作用。

• 批准号: 304636
• 负责人: Aoudjit Fawzi
• 金额: $ 41.34万
• 依托单位: Centre hospitalier de l'Universit Laval (Qubec)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2014
• 资助国家: 加拿大
• 起止时间: 2014-03-01 至 2019-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=304636&lang=en
• 关键词: Animal Models; Apoptosis; Cell Adhesion; Chemoresistance; Flow Cytometry; Growth; Integrin Signaling; T Cell Leukemia

Leukemia and lymphoma (T cell malignancies) are among the fastest rising cancers in North America. For example, acute T lymphoblastic leukemia (T-ALL) accounts for approximately 15% of all childhood leukemia and for 25 % of all adult leukemia. The cellula

白血病和淋巴瘤（T 细胞恶性肿瘤）是北美增长最快的癌症之一。例如，急性 T 淋巴细胞白血病 (T-ALL) 约占所有儿童白血病的 15%，约占所有成人白血病的 25%。细胞